Value‐based healthcare emphasizes outcomes that matter to patients, and patient‐centred outcomes sets are vital to its success. For psoriasis, initial work proposed a patient‐centred outcomes set in Belgium, but it requires further validation to ensure international applicability. This scoping study aimed to refine the outcomes set in collaboration with patient representatives and dermatologists, in preparation for international validation through a Delphi consensus process. An international Working Group of patient representatives and dermatologists was established through the International Federation for Psoriasis Associations (IFPA) and the International Psoriasis Council (IPC). Experts participated in three discussion meetings and subsequent surveys to discuss and recommend outcomes important to people living with psoriasis, their measurement and case‐mix variables. The systematic review of patient‐relevant outcomes was updated as well and outcome measurement instruments were selected corresponding to the COSMIN criteria. The Working Group included 35 experts (12 patient representatives and 23 dermatologists) from 22 countries. A total of three discussion meetings and two subsequent surveys informed the refinement of the outcomes set. ‘Acceptable costs of care for society’ was excluded as an outcome, four outcomes were merged into ‘psoriasis clearance’ and ‘social activity’, and ‘communication’ and ‘confidence in care’ were reclassified as patient experiences. ‘Feelings of stigmatization’ and ‘number of flare‐ups’ were added based on patient recommendations. These changes resulted in a revised set of 18 patient‐relevant outcomes and 2 patient experiences. After selecting outcome measurement instruments, a heatmap was compiled to assess overlap, quality and feasibility. Finally, 50 case‐mix variables were proposed based on the literature and expert opinions. This scoping study convened an international Working Group of patient representatives and dermatologists to establish the fundamentals for a patient‐centred outcomes set. The subsequent Delphi process will finalize consensus, advancing value‐based psoriasis management worldwide. People living with psoriasis often experience more than just skin symptoms; the disease can affect their daily life, emotional well‐being and other health problems, including comorbidities. To improve psoriasis management, doctors and patients need to agree on what outcomes matter most and how to measure them. This study is part of a larger international project that aims to develop a patient‐centred outcomes set for psoriasis, meaning a list of outcomes that reflect patients’ real priorities. This international project consists of three phases. In the initial phase, the project team first reviewed the literature and worked with Belgian patients to create an initial set of 21 patient‐relevant outcomes. To make this list useful, relevant and applicable internationally, we then brought together 35 experts, including 12 patient representatives and 23 dermatologists from 22 countries, for online meetings and surveys during the scoping phase. Together, the experts reviewed and refined the outcomes and their definitions, outcome measurement instruments and factors that can influence patient outcomes (i.e. case‐mix variables). As a result, the group proposed a revised set of 18 patient‐relevant outcomes and 2 patient experiences. The final phase will be an international Delphi study, in which a larger group of experts will vote to reach final agreement. Once validated and implemented, this patient‐centred outcomes set will help patients and clinicians worldwide to focus on what truly matters in psoriasis care, improving quality of life, achieving better outcomes and supporting personalized management for people living with psoriasis. This scoping study refined the first patient‐centred outcome set for psoriasis, involving patient representatives and dermatologists from 22 countries. The proposal includes 18 patient‐relevant outcomes, 2 patient experiences, corresponding outcome measurement instruments and 50 case‐mix variables. These findings form the foundation for an international Delphi process to reach global consensus.